BIOLASE, Inc. – NASDAQ:BIOL
BIOLASE stock price today
$0.058
-0.02
-29.15%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
BIOLASE stock price monthly change
-44.97%
month
BIOLASE stock price quarterly change
-54.90%
quarter
BIOLASE stock price yearly change
+0.12%
year
BIOLASE key metrics
Market Cap | 731.94K |
Enterprise value | N/A |
P/E | -0.06 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 0.04 |
Price/Book | 0.41 |
PEG ratio | N/A |
EPS | -14.94 |
Revenue | 48.82M |
EBITDA | -14.54M |
Income | -21.26M |
Revenue Q/Q | -3.21% |
Revenue Y/Y | 0.13% |
Profit margin | -59.09% |
Oper. margin | -52.29% |
Gross margin | 32.83% |
EBIT margin | -52.29% |
EBITDA margin | -29.78% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBIOLASE stock price history
BIOLASE stock forecast
BIOLASE financial statements
| Jun 2023 | 14.28M | -4.86M | -34.08% |
|---|---|---|---|
| Sep 2023 | 10.92M | -4.58M | -42.02% |
| Dec 2023 | 13.49M | -5.32M | -39.48% |
| Mar 2024 | 10.13M | -6.48M | -64.01% |
| Mar 2024 | 10.13M | -6.48M | -64.01% |
|---|---|---|---|
| Sep 2025 | 12.5M | -60.62K | -0.48% |
| Oct 2025 | 12.45M | -356.84K | -2.87% |
| Dec 2025 | 17.1M | 178.42K | 1.04% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 39633000 | 32.29M | 81.48% |
|---|---|---|---|
| Sep 2023 | 38745000 | 32.86M | 84.81% |
| Dec 2023 | 35101000 | 35.34M | 100.7% |
| Mar 2024 | 34353000 | 36.28M | 105.63% |
| Jun 2023 | -3.56M | -357K | 4.27M |
|---|---|---|---|
| Sep 2023 | -2.58M | -182K | 3.75M |
| Dec 2023 | -2.28M | -3K | 885K |
| Mar 2024 | -5.93M | 197K | 5.64M |
BIOLASE alternative data
| Aug 2023 | 188 |
|---|---|
| Sep 2023 | 188 |
| Oct 2023 | 188 |
| Nov 2023 | 188 |
| Dec 2023 | 188 |
| Jan 2024 | 188 |
| Feb 2024 | 188 |
| Mar 2024 | 157 |
| Apr 2024 | 157 |
| May 2024 | 157 |
| Jun 2024 | 157 |
| Jul 2024 | 157 |
BIOLASE other data
23.94%
+12.45%
of BIOL is owned by hedge funds
16
-12
1.45M
+756.56K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 0 | 3537 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | LORD JONATHAN T MD director | Common Stock | 3,537 | $0.75 | $2,653 | ||
Sale | LORD JONATHAN T MD director | Common Stock | 11,038 | $0.38 | $4,194 | ||
Purchase | BEAVER JOHN R director, officer.. | Common Stock | 70,000 | $0.45 | $31,500 | ||
Purchase | BEAVER JOHN R officer: EVP & Ch.. | Common Stock | 35,000 | $0.61 | $21,350 | ||
Purchase | BEAVER JOHN R officer: EVP & Ch.. | Common Stock | 40,000 | $0.75 | $30,000 | ||
Sale | FEINBERG LARRY N 10 percent owner | Common Stock | 1,759,912 | $0.55 | $969,712 | ||
Sale | FEINBERG LARRY N 10 percent owner | Common Stock | 1,759,912 | $0.55 | $969,712 | ||
Sale | FEINBERG LARRY N 10 percent owner | Common Stock | 923,482 | $0.55 | $511,609 | ||
Sale | FEINBERG LARRY N 10 percent owner | Common Stock, par value $0.001 per share ("Common Stock") | 2,479,456 | $0.55 | $1,373,619 | ||
Sale | SCHULER JACK W 10 percent owner | Common Stock | 1,307,931 | $0.6 | $784,759 |
| Patent |
|---|
Application Filling date: 4 Jan 2022 Issue date: 30 Jun 2022 |
Application Filling date: 4 Oct 2021 Issue date: 30 Jun 2022 |
Application Filling date: 17 Nov 2021 Issue date: 16 Jun 2022 |
Application Filling date: 15 Nov 2021 Issue date: 10 Mar 2022 |
Grant Filling date: 25 Nov 2020 Issue date: 15 Feb 2022 |
Application Filling date: 17 Aug 2021 Issue date: 3 Feb 2022 |
Application Filling date: 3 Aug 2021 Issue date: 27 Jan 2022 |
Application Filling date: 28 Jul 2021 Issue date: 20 Jan 2022 |
Grant Utility: Dental system and method Filling date: 21 Dec 2017 Issue date: 21 Dec 2021 |
Grant Filling date: 21 Oct 2019 Issue date: 7 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. John R. Beaver (1961) Pres, Chief Executive Officer & Director | $309,830 |
-
What's the price of BIOLASE stock today?
One share of BIOLASE stock can currently be purchased for approximately $0.06.
-
When is BIOLASE's next earnings date?
Unfortunately, BIOLASE's (BIOL) next earnings date is currently unknown.
-
Does BIOLASE pay dividends?
No, BIOLASE does not pay dividends.
-
How much money does BIOLASE make?
BIOLASE has a market capitalization of 731.94K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1.45% to 49.16M US dollars.
-
What is BIOLASE's stock symbol?
BIOLASE, Inc. is traded on the NASDAQ under the ticker symbol "BIOL".
-
What is BIOLASE's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of BIOLASE?
Shares of BIOLASE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BIOLASE's key executives?
BIOLASE's management team includes the following people:
- Mr. John R. Beaver Pres, Chief Executive Officer & Director(age: 64, pay: $309,830)
-
How many employees does BIOLASE have?
As Jul 2024, BIOLASE employs 157 workers.
-
When BIOLASE went public?
BIOLASE, Inc. is publicly traded company for more then 32 years since IPO on 12 Nov 1992.
-
What is BIOLASE's official website?
The official website for BIOLASE is biolase.com.
-
Where are BIOLASE's headquarters?
BIOLASE is headquartered at 27042 Towne Centre Drive, Foothill Ranch, CA.
-
How can i contact BIOLASE?
BIOLASE's mailing address is 27042 Towne Centre Drive, Foothill Ranch, CA and company can be reached via phone at +94 93611200.
BIOLASE company profile:
BIOLASE, Inc.
biolase.comExchange:
NASDAQ
Full time employees:
157
Industry:
Medical - Devices
Sector:
Healthcare
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
27042 Towne Centre Drive
Foothill Ranch, CA 92610-2811
Foothill Ranch, CA 92610-2811
CIK: 0000811240
ISIN: US0909117022
CUSIP: 090911207
